pharma · Nasopharyngeal Carcinoma · Hepatocellular Carcinoma
Chinese Academy of
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chinese Academy of is a pharma organization headquartered in TAIZHOU, CN. Primary therapeutic focus areas include Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, COVID-19, Breast Cancer, Coronary Artery Disease. Nova
China, TAIZHOU, CN HQ
170 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- China, TAIZHOU, CN
- Employees
- 170
- Programs
- 1328
- Drugs
- 711
- Patents
- 335
Vebreltinib
Phase 2 · small molecule · Potentially Resectable MET-altered Non-Small Cell Lung Cancer
Vebreltinib for Potentially Resectable MET-altered Non-Small Cell Lung Cancer is a Phase 2 program (small_molecule) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).
Internal code LungMate-025
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Potentially Resectable MET-altered Non-Small Cell Lung Cancer
- Status
- active
- Trials
- 1